MRM Health and IFF Reach Second Milestone in the Partnered Type 2 Diabetes Program

2022年12月16日 09:16:13 来自: (0)参与

GHENT, Belgium -- (BUSINESS WIRE) --

MRM Health—a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics—today announced that its Type-2 Diabetes Program, developed in collaboration with IFF (NYSE: IFF) has achieved preclinical development targets. With the achievement of this new milestone, both companies will now advance this research which focuses on developing innovative therapies for metabolic diseases to the clinical development stage.

IFF joined forces with microbiome specialist MRM Health in 2020, aiming to tackle a range of metabolic diseases. In this research, the proprietary MRM Health CORAL® technology platform and some selected IFF strains will be combined to develop novel therapeutics based on live bacterial strain combinations.

We are very pleased to see the progress that MRM Health and IFF have made within our partnership programs in metabolic health,” said Oliver Hasselwander, technical fellow, IFF. “By reaching this preclinical milestone in the diabetes program, MRM Health has further demonstrated that their technology platform is unique in identifying next generation microbiome solutions, and we look forward to developing these together with MRM Health.”

The gut microbiome has a recognized role in non-alcoholic fatty liver disease (NAFLD) and associated diseases such as Type-2 diabetes and obesity. The two companies will continue the NAFLD program to further build on promising lead consortia. IFF and MRM Health’s collaboration on NAFLD will enable both parties to build upon the preclinical results, showing that a nine-strain bacterial consortium delays NAFLD progression and liver fibrosis. Part of this work was recently published in Biomedicines.

"This second milestone achievement is an important step in demonstrating our team's expertise and the capacity of our unique CORAL® platform to deliver differentiated microbiome therapeutics across different diseases,” said Sam Possemiers, CEO and co-founder of MRM Health. “We are delighted to be working with IFF to rapidly drive the program through this preclinical phase, and we are confident that our technologies have the potential to deliver future life-changing oral therapeutics for patients."

MRM Health’s CORAL® platform utilizes a bioinformatics-guided in-human discovery engine, combined with a breakthrough in optimization and manufacturing of consortia as single drug substance. The proprietary consortia optimization technology allows for the development of next-generation consortia therapeutics with faster onset-of-action and increased potency and robustness. The breakthrough scalable, robust, and standardized cGMP-compliant consortia manufacturing technology allows to manufacture complete therapeutic consortia as a single drug substance in a single manufacturing process which strongly surpasses existing approaches in speed, reduced complexity, increased robustness and lower cost.

About MRM Health

MRM Health NV, Ghent, Belgium, is a biopharmaceutical company focused on the development of next-generation optimized consortium therapeutics based on the human microbiome. The company has built a diversified pipeline with its proprietary CORAL® platform to design, optimize, and manufacture bacterial consortia as single drug substance. Its most advanced program MH002 is an optimized consortium of 6 rationally-selected and well-characterized commensal strains. MH002 is currently being studied in two Phase 2 studies in patients with mild-to-moderate Ulcerative Colitis and acute Pouchitis, respectively. Additional pipeline development includes a preclinical program in Parkinson’s disease, preclinical programs in Type 2 Diabetes and in NAFLD (both partnered with IFF, previously DuPont), and a discovery program in autoimmune disease, including spondyloarthritis.

Welcome to IFF

At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.

** END**

View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005040/en/

CONTACT:

For further information please contact:

Dr Sam Possemiers – CEO
Christiane Verhaegen – CFO
Phone: +32.9.277.08.50
info@mrmhealth.com

相关新闻
搜狐网友:情歌两三首ㄨ
评论:长寿秘诀——保持呼吸,不要断气。

天涯网友:黒色曼陀罗
评论:老师说过早恋是不好的,我们很听话,只会暗恋

百度网友:Paranoid. 偏执
评论:“高富帅官二代”这六个字,我想我只做到了第五个字。

天猫网友:虐恋sadomasochism
评论:今天情人节出去玩,卖花的小姑娘拉着我:“大哥哥,买花吧,一看就知道你是花心的人”……

其它网友:忘了爱° Toro
评论:如果你看到面前的阴影,别怕,那是因为你的背后有阳光!

本网网友:旧言虐心, -Eros
评论:据说两男一女走在街上,三人都会觉得自己是电灯泡。

腾讯网友:ゆ.咬破红唇
评论:破锅自有破锅盖,尼姑自有和尚爱

猫扑网友:曲终人离场
评论:你都好意思骗我了,我哪好意思不信。

凤凰网友:喜新 tunesd
评论:有人说我懒得抽筋,其实我连抽筋都懒得抽

淘宝网友:念旧-  Tender
评论:我还没年轻到什么都懂的地步。

新闻转自网络媒体,如有侵权,请与我们联系:1160322105@qq.com责编:admin